|
Indeed,
there are over 600,000 needle-stick injuries every year in the
US to healthcare professionals, leading to the risk of infection
by diseases such as hepatitis B, C and HIV.
Current "needle
free" injection systems using CO2 or spring compression
to force a drug through the skin into the subcutaneous tissue
can be expensive, loud, cumbersome, and can cause injury to the
patient. These systems often require special training for use
and maintenance and have not enjoyed widespread use with self-administered
drugs. Passive transdermal delivery of large molecules using
patch systems has so far been unsuccessful due to the skins
lack of permeability, and only small molecules like nicotine
have been deliverable with this methodology. Active transdermal
techniques, employing either electrical or chemical enhancement,
have shown some early signs of success; however, they have sustained
difficulties with formulation stability and have the potential
to cause skin irritation.
MicroDose
has conceived a battery operated, electromechanical device that
controls the needlefree injection of micro-liter quantities of
a drug in rapid pulses until the entire volume is delivered.
Unlike systems using iontophoresis or electroporation, our system
will be able to deliver both small and large molecules. The system
can be designed as a standard pen injector for use by patients
who are skilled at self-injection, but it can also be designed
to be worn as a patch, which can be programmed for intermittent
or continuous delivery, allowing the appropriate amount of medication
to be given at a predetermined time. The patch design would be
most helpful for children and patients who are unable or unwilling
to give themselves injections, and for those patient groups that
are poorly compliant. The system would be safe and simple to
use, inexpensive, quiet, and would use drugs prepackaged specifically
for a unit dose pack to eliminate cleaning and assure correct
dosing.
MicroDose's
non-invasive, needlefree delivery system approach overcomes the
problems associated with needle injections and alternative needlefree
systems, offering significant benefits to patients, healthcare
professionals and pharmaceutical manufacturers.
Using
this technology for injections would virtually eliminate the
associated risk of contaminated needle stick injuries and resulting
blood-borne pathogen transmission, a major concern throughout
the healthcare industry.
MicroDose's
needlefree approaches, while patented, are now only in the conceptual
stage. Development plans through rapid proof-of-concept have
been developed and can be initiated upon demonstration of interest
by potential partners.
|
|